You Might Also Be
Interested In
Latham “has an impressive spread of life sciences capabilities around the world.”  Chambers Global 2013

Life Science Licensing

Deep experience structuring and negotiating strategic partnering, joint venture and co-development agreements.

Test Tubes

Latham & Watkins’ Life Science Licensing Practice emphasizes practical solutions to complex life sciences transactions and partnerships. Many of the firm’s lawyers have advanced scientific and business degrees, are qualified to practice before the US Patent and Trademark Office (USPTO), and have held legal and scientific positions within high-profile life science companies.

Latham has deep experience advising clients on life sciences-related transactions, such as:

  • Complex global strategic alliances, joint ventures, spinouts and other special purpose business structures
  • Intellectual property licensing, monetization and exploitation
  • Co-development and co-promotion agreements
  • Academic and research agreements
  • Manufacturing, supply and distribution agreements
  • Intellectual property advice in support of mergers, acquisitions or divestitures of genomics, pharmaceutical and medical device assets
  • Day-to-day counseling on commercial transactions

The lawyers’ in-depth knowledge of the life sciences markets and the science that underpins them enables the firm to work with its clients to identify, conceptualize and develop creative solutions to the business and legal issues that arise in the course of a complex life sciences transaction.

Latham’s Life Sciences Licensing practice has experience in the full spectrum of life sciences industry sectors, including biologics, biosimilars, diagnostics and medical devices,  pharmaceuticals and therapeutics. We have advised clients in complex deals that have been nominated for or won industry-leading awards such as In Vivo’s “Alliance of the Year,” BayBio’s Pantheon DiNA Outstanding Partnering Award and Licensing Executives Society “Deals of Distinction.” 

Other notable recent experience includes:

  • Prothena’s Collaboration with Roche: Development and commercialization of antibodies for the treatment of Parkinson’s disease, valued up to US$600 million
  • Allergan’s Collaboration with Medytox: Development and commercialization of certain neurotoxin product candidates, valued up to US$360 million
  • Chiasma’s Collaboration with Roche: Development and commercialization of a drug for the treatment of acromegaly, valued up to US$595 million
  • Novo A/S’s Royalty Purchase and Investment in Ophthotech Corporation: Novo purchased royalties on sales of Fovista, an anti-platelet-derived growth factor, and made an equity investment in Ophthotech, valued up to US$175 million
  • Coherus Biosciences’ Collaboration with Baxter: Development and commercialization of a biosimilar to etanercept for certain regional markets, valued up to US$246 million
  • Actavis’ Partnership with Medicines360: Marketing, sales and distribution of LNG20, an intrauterine device, in the private sector commercial markets in the U.S. and Canada, valued up to US$175 million
  • Orchid Pharma’s Partnership with Allecra Therapeutics: Development of  novel antibiotics to combat multi-drug resistant bacterial infections
more
 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.